Business
DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022
MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments
About this update from Diamedica Therapeutics Inc.
[{"type":"text","content":" MINNEAPOLIS--(BUSINESS WIRE)--\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company’s management team will be participating in one-on-one meetings at the upcoming BTIG Biotechnology Conference, which is taking place both virtually and at the St. Regis New York Hotel in New York City, August 8-9, 2022.\n\nFor those interested in meeting with DiaMedica at the conference, please reach out to your BTIG representative to schedule a meeting.\n\nAbout DiaMedica Therapeutics\n\nDiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant form of the human tissue kallikrein-1 protein (KLK1), an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit our website at www.diamedica.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20220801005734/en/\n\nScott Kellen\nChief Financial Officer\nPhone: (763) 496-5118\[email protected]\n\nPaul Papi\nCorporate Communications\nPhone: 617-899-5941\[email protected]\n\nSource: DiaMedica Therapeutics Inc.","length":2821,"tagName":"div"}]